Shanghai Rendu Biotechnology Co., Ltd. Class A

As of June 30, 2026, Shanghai Rendu Biotechnology Co., Ltd. Class A carries a market capitalization of 2.22B, placing it among publicly traded companies globally. Its enterprise value stands at 1.46B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Shanghai Rendu Biotechnology Co., Ltd. Class A has 40.07M shares outstanding.

As of June 30, 2026, Shanghai Rendu Biotechnology Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 162.10. The price-to-sales ratio is 13.41, and the price-to-book ratio stands at 2.51.

As of June 30, 2026, Shanghai Rendu Biotechnology Co., Ltd. Class A trades at an EV/EBITDA multiple of 106.41 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 8.97 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 106.41 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.46B versus a market cap of 2.22B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Shanghai Rendu Biotechnology Co., Ltd. Class A maintains a current ratio of 14.94, meaning it holds 14.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.53, indicating moderate leverage, while an interest coverage ratio of 72.25 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Shanghai Rendu Biotechnology Co., Ltd. Class A posted a return on equity (ROE) of 1.50, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 1.39, measuring how efficiently the asset base is converted into earnings. The company generates approximately 618,945.94 in revenue per employee across its workforce of 263.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.57 indicates how many times Shanghai Rendu Biotechnology Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Shanghai Rendu Biotechnology Co., Ltd. Class A recorded an income tax benefit of -52,747.16 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 13.41M, leaving 13.47M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Shanghai Rendu Biotechnology Co., Ltd. Class A's stock has declined approximately 8.17% over the past 52 weeks. The 50-day moving average sits at 47.79, while the 200-day moving average is 50.29.

Over the twelve months ended June 30, 2026, Shanghai Rendu Biotechnology Co., Ltd. Class A generated 162.78M in revenue and converted that into 13.47M in net income, yielding earnings per share of 0.34. EBITDA reached 13.73M, while operating income came in at -3.33M.

As of June 30, 2026, Shanghai Rendu Biotechnology Co., Ltd. Class A holds 759.79M in cash and equivalents against 4.69M in total debt, resulting in a net debt position of -136.97M. Total book value stands at 884.07M, with working capital of 800.51M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai Rendu Biotechnology Co., Ltd. Class A posted a gross margin of 79.07, reflecting its pricing power and cost economics. The operating margin of -2.04 and net profit margin of 8.27 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Shanghai Rendu Biotechnology Co., Ltd. Class A paid dividends of 0.15 per share. The dividend payout ratio of 43.20 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.30, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Shanghai Rendu Biotechnology Co., Ltd. Class A shareholders.

As of June 30, 2026, Shanghai Rendu Biotechnology Co., Ltd. Class A has an Altman Z-Score of 21.94, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.